Lv51
1370 积分 2025-04-14 加入
[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)]
6小时前
已完结
Non-small-cell lung cancer
7小时前
已完结
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer
29天前
已完结
Unresectable stage III non-small-cell lung cancer: state of the art and challenges
1个月前
已完结
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
1个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
2个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
2个月前
已完结
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
3个月前
已完结
Regulatory T cells in the tumour microenvironment
3个月前
已完结
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
3个月前
已完结
皖公网安备34019202002308
